BCBP Seminar: "Targeting Cell Signaling Pathways for Cancer Therapies"

Wenyi Wei of Beth Israel Deaconess Medical Center and Harvard Medical School will present her seminar August 28 at 11 am in 1131 Bioinformatics.

When Aug 28, 2018
from 11:00 AM to 12:00 PM
Where Bioinformatics 1131
Contact Name
Contact Phone 919-843-9986
Add event to calendar vCal
iCal

Wenyi Wei, PhD
Professor, Department of Pathology
Beth Israel Deaconess Medical Center
Harvard Medical School
http://www.hms.harvard.edu/dms/bbs/fac/wei.php
Host: Pengda Liu, PhD, UNC Biochemistry and Biophysics Assistant Professor 


"Targeting Cell Signaling Pathways for Cancer Therapies"


My laboratory mainly focuses on understanding mechanistically how aberrant cell signaling events lead to altered protein homeostasis and cellular functions to facilitate the development of human disorders including cancer. Our research is uniquely poised to understand how post-translational modifications including lysine ubiquitination, acetylation and methylation generate a complex coding system to transduce cellular messages, and crosstalk with other signaling pathways, such as well-studied kinase-cascades, to govern various cellular processes. One of the major focus lies in understanding how aberrant cell cycle regulation leads to cancer development. To this end, proper cell cycle transitions are largely driven by waves of ubiquitin-dependent degradation of key cell cycle regulators by APC or SCF, the two major E3 ligase complexes. Thus one of the main research focus in my laboratory at Department of Pathology, BIDMC is focused on understanding how APC and SCF activities contribute towards cell cycle regulation and subsequent tumor formation. I will present new information regarding our dedicated efforts in utilizing multidisciplinary approaches including biochemical and genetic analysis to understand the tumor suppressor role of Cdh1 or Fbw7 and the oncogenic potential of Skp2, as well as in defining the molecuar mechanisms underlying how frequent activaiton of the PI3K/Akt/mTOR onogenic signaling pathway drives tumoirgenesis. These results will help to better understand the multilayer regulation of the delicate network of signaling pathways and their physiologica contribution to cancer development, which will lead us to the design of more efficient intervention strategies to combat cancer and other diseases.